Filtered By:
Drug: Polyethylene Glycol

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Antiproliferative activity of CD44 siRNA-PEI-PEG nanoparticles in glioblastoma: involvement of AKT signaling
CONCLUSION AND IMPLICATIONS: Our results suggest that PEI-PEG-loaded CD44 siRNA may attenuate the cell cycle by suppressing AKT signaling pathway.PMID:34909046 | PMC:PMC8621842 | DOI:10.4103/1735-5362.329928
Source: Cell Research - December 15, 2021 Category: Cytology Authors: Parvaneh Mahinfar Ahad Mokhtarzadeh Behzad Baradaran Elham Siasi Torbati Source Type: research

Influence of protein corona on the interaction of glycogen-siRNA constructs with ex vivo human blood immune cells
This study provides an insight into the rational design of glycogen-based nanocarriers for the safe delivery of siRNA without eliciting unwanted immune cell activation and efficient siRNA activity upon its delivery.PMID:36027666 | DOI:10.1016/j.bioadv.2022.213083
Source: Cancer Control - August 26, 2022 Category: Cancer & Oncology Authors: Marcin Wojnilowicz Petra Laznickova Yi Ju Ching-Seng Ang Federico Tidu Kamila Bendickova Giancarlo Forte Magdalena Plebanski Frank Caruso Francesca Cavalieri Jan Fric Source Type: research

Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
Abstract Efficient and targeted cellular delivery of small interfering RNAs (siRNAs) and antisense oligonucleotides (AONs) is a major challenge facing oligonucleotide-based therapeutics. The majority of current delivery strategies employ either conjugated ligands or oligonucleotide encapsulation within delivery vehicles to facilitate cellular uptake. Chemical modification of the oligonucleotides (ONs) can improve potency and duration of activity, usually as a result of improved nuclease resistance. Here we take advantage of innovations in both polymeric delivery vehicles and ON stabilization to achieve receptor-me...
Source: Biomaterials - August 7, 2013 Category: Materials Science Authors: Chan DP, Deleavey GF, Owen SC, Damha MJ, Shoichet MS Tags: Biomaterials Source Type: research

Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery.
Abstract Targeted delivery of therapeutic genes to the tumor site is critical for successful and safe cancer gene therapy. The arginine grafted bio-reducible poly (cystamine bisacrylamide-diaminohexane, CBA-DAH) polymer (ABP) conjugated poly (amido amine) (PAMAM), PAM-ABP (PA) was designed previously as an efficient gene delivery carrier. To achieve high efficacy in cancer selective delivery, we developed the tumor targeting bio-reducible polymer, PA-PEG1k-RGD, by conjugating cyclic RGDfC (RGD) peptides, which bind αvβ3/5 integrins, to the PAM-ABP using polyethylene glycol (PEG, 1 kDa) as a spacer. Physical cha...
Source: Biomaterials - May 31, 2014 Category: Materials Science Authors: Kim HA, Nam K, Kim SW Tags: Biomaterials Source Type: research

Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.
Abstract Fibrotic diseases such as scleroderma have been linked to increased oxidative stress and upregulation of pro-fibrotic genes. Recent work suggests a role of NADPH oxidase 4 (NOX4) and heat shock protein 47 (HSP47) in inducing excessive collagen synthesis, leading to fibrotic diseases. Herein, we elucidate the relationship between NOX4 and HSP47 in fibrogenesis and propose to modulate them altogether as a new strategy to treat fibrosis. We developed a nanoparticle platform consisting of polyethylenimine (PEI) and polyethylene glycol (PEG) coating on a 50-nm mesoporous silica nanoparticle (MSNP) core. The na...
Source: Biomaterials - July 10, 2015 Category: Materials Science Authors: Morry J, Ngamcherdtrakul W, Gu S, Goodyear SM, Castro DJ, Reda MM, Sangvanich T, Yantasee W Tags: Biomaterials Source Type: research

Hypoxia-Responsive Copolymer for siRNA Delivery
A wide variety of nanomedicine has been designed for cancer therapy. Herein, we describe the synthesis and evaluation of a hypoxia-responsive copolymer for siRNA delivery (Perche et al., Angew Chem Int Ed Engl 53:3362–3366, 2014). The synthesis is achieved using established coupling chemistry and accessible purification procedures. A polyelectrolyte-lipid conjugate (polyethyleneimine 1.8 kDa-dioleyl-phosphatidylinositol, PEI-PE) and polyethylene glycol 2000 (PEG) were assembled via the hypoxia-sensitive azobenzene (Azo) unit to obtain the PEG-Azo-PEI-DOPE copolymer. This copolymer can condense siRNA and shows hypoxia...
Source: Springer protocols feed by Imaging/Radiology - October 11, 2015 Category: Radiology Source Type: news

Plasmid-Based Stat3 siRNA Delivered by Functional Graphene Oxide Suppresses Mouse Malignant Melanoma Cell Growth.
Authors: Yin D, Li Y, Guo B, Liu Z, Xu Y, Wang X, Du Y, Xu L, Meng Y, Zhao X, Zhang L Abstract RNA interference (RNAi) has been used for cancer gene therapy in recent years. However, the application of RNAi is hindered in the absence of safe and efficient gene delivery. In this article, a novel vehicle of graphene oxide functionalized with polyethylenimine and polyethylene glycol (GO-PEI-PEG) was successfully synthetized and then used to deliver plasmid-based Stat3 siRNA. The carrier can readily bind plasmid with high transfection efficiency. Moreover, molecular biology studies reveal that Stat3-related gene and pr...
Source: Oncology Research - April 23, 2016 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device.
In conclusion, I succeeded in developing a new therapy based on regulation of the tumor microenvironment. PMID: 31685731 [PubMed - in process]
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - November 8, 2019 Category: Drugs & Pharmacology Authors: Sakurai Y Tags: Yakugaku Zasshi Source Type: research

Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
In this study, LNP-DP1 –a cationic lipid nanoparticle formulation –is reported as a vehicle to restore deregulated gene expression in hepatic carcinoma cells by siRNA and miRNA delivery using a mouse model. Further expansions to this study may enable transition to clinical trials of this system.Graphical Abstract: The schematic representation of mi-/si-RNA encapsulated by PEG modified LNP-DP1 which is mainly composed of EggPC, cholesterol and cationic lipid DODMA. The LNP-DP1 (red particles) can be specifically and efficiently taken up by hepatocytes and tumor cells (blue nuclei and green cell outline) after delivery t...
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - June 3, 2013 Category: Nanotechnology Authors: Shu-hao Hsu, Bo Yu, Xinmei Wang, Yuanzhi Lu, Carl R. Schmidt, Robert J. Lee, L. James Lee, Samson T. Jacob, Kalpana Ghoshal Tags: Genetics, Gene Delivery, HEP-CC, Micro-RNA Delivery, Cationic Lipid NPs Source Type: research

In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl- β-Cyclodextrin Conjugate
AbstractWe have previously reported the utility of folate-polyethylene glycol-appended dendrimer conjugate with glucuronylglucosyl- β-cyclodextrin (Fol-PEG-GUG-β-CDE) (generation 3) as a tumor-selective carrier for siRNA against polo-like kinase 1 (siPLK1)in vitro. In the present study, we evaluated the potential of Fol-PEG-GUG- β-CDE as a carrier for the low-molecular antitumor drug doxorubicin (DOX). Further, to fabricate advanced antitumor agents, we have prepared a ternary complex of Fol-PEG-GUG-β-CDE/DOX/siPLK1 and evaluated its antitumor activity bothin vitro andin vivo. Fol-PEG-GUG- β-CDE released DOX in an aci...
Source: The AAPS Journal - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance
AbstractND-L02-s0201/BMS-986263 is a lipid nanoparticle (LNP) drug product containing a heat shock protein 47 (HSP47) –specific small interfering ribonucleic acid (siRNA) and being developed for the treatment of liver and idiopathic pulmonary fibrosis. To address immunogenicity-related issues, we developed a robust, fit-for-purpose (FFP) three-tier electrochemiluminescent (ECL) anti-drug antibody (ADA) assay for the detection of antibodies (Abs) generated to surface-exposed components of BMS-986263. The drug was coated directly on plates, and several Abs specific for polyethylene glycol (PEG) and other surface components...
Source: The AAPS Journal - July 21, 2019 Category: Drugs & Pharmacology Source Type: research

Microencapsulated Multifunctionalized Graphene Oxide Equipped with Chloroquine for Efficient and Sustained siRNA Delivery
Biomed Res Int. 2022 Apr 6;2022:5866361. doi: 10.1155/2022/5866361. eCollection 2022.ABSTRACTA multifunctionalized graphene oxide (GO)-based carrier with conjugation of aminated-polyethylene glycol (PEG-diamine), octaarginine (R8), and folic acid (FA), which also contains chloroquine (CQ), a lysosomotropic agent, is introduced. The cellular uptake mechanisms and intracellular targeting of FA-functionalized nanocarriers are examined. The localized releases of CQ and siRNA intracellular delivery are evaluated. Microencapsulation of the nanocarrier complexed with genes in layer-by-layer coating of alginate microbeads is also ...
Source: Cell Research - April 26, 2022 Category: Cytology Authors: Rana Imani Satya Prakash Hojatollah Vali John F Presley Shahab Faghihi Source Type: research

AI-16 * HIF-1a INHIBITION BY RNA INTERFERENCE DELIVERED VIA A NOVEL MULTIFUNCTIONAL SURFACTANT ATTENUATES GLIOMA GROWTH IN AN INTRACRANIAL MOUSE MODEL
CONCLUSIONS: Treating glioblastoma with siRNA targeting HIF-1α in vivo can significantly reduce tumor growth and increase survival in an intracranial mouse model. Our novel siRNA carrier improves delivery of this treatment molecule. With further study this might be extended for use in human patients with malignant gliomas.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Jensen, R., Gillepsie, D. Tags: ANGIOGENESIS AND INVASION (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research

Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation
ConclusionPEG ‐PEI‐EGFR‐siRNA nanocomposites may be a supplemental therapy strategy to treat residual lung cancer after incomplete MWA.
Source: Thoracic Cancer - April 23, 2019 Category: Cancer & Oncology Authors: Fei Cao, Chao Wan, Lin Xie, Han Qi, Lujun Shen, Shuanggang Chen, Ze Song, Weijun Fan Tags: ORIGINAL ARTICLE Source Type: research